This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
ELV or PGNY: Which Is the Better Value Stock Right Now?
by Zacks Equity Research
ELV vs. PGNY: Which Stock Is the Better Value Option?
Wall Street Analysts See a 64% Upside in Progyny (PGNY): Can the Stock Really Move This High?
by Zacks Equity Research
The consensus price target hints at a 63.5% upside potential for Progyny (PGNY). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
Progyny (PGNY) Q3 Earnings and Revenues Top Estimates
by Zacks Equity Research
Progyny (PGNY) delivered earnings and revenue surprises of 160% and 5.64%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
ELV or PGNY: Which Is the Better Value Stock Right Now?
by Zacks Equity Research
ELV vs. PGNY: Which Stock Is the Better Value Option?
Progyny (PGNY) Upgraded to Buy: Here's What You Should Know
by Zacks Equity Research
Progyny (PGNY) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
AMN or PGNY: Which Is the Better Value Stock Right Now?
by Zacks Equity Research
AMN vs. PGNY: Which Stock Is the Better Value Option?
MODV vs. PGNY: Which Stock Is the Better Value Option?
by Zacks Equity Research
MODV vs. PGNY: Which Stock Is the Better Value Option?
Does Progyny (PGNY) Have the Potential to Rally 64% as Wall Street Analysts Expect?
by Zacks Equity Research
The average of price targets set by Wall Street analysts indicates a potential upside of 63.5% in Progyny (PGNY). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
MODV vs. PGNY: Which Stock Should Value Investors Buy Now?
by Zacks Equity Research
MODV vs. PGNY: Which Stock Is the Better Value Option?
Can Progyny (PGNY) Climb 47% to Reach the Level Wall Street Analysts Expect?
by Zacks Equity Research
The average of price targets set by Wall Street analysts indicates a potential upside of 46.6% in Progyny (PGNY). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
AMN vs. PGNY: Which Stock Should Value Investors Buy Now?
by Zacks Equity Research
AMN vs. PGNY: Which Stock Is the Better Value Option?
Progyny (PGNY) Q2 Earnings and Revenues Beat Estimates
by Zacks Equity Research
Progyny (PGNY) delivered earnings and revenue surprises of 350% and 2.24%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
Molina Healthcare (MOH) to Buy My Choice Wisconsin for $150M
by Zacks Equity Research
Molina Healthcare (MOH) expects the buyout to complement its existing Medicaid business in Wisconsin.
Encompass Health (EHC) to Build New Rehab Unit in Missouri
by Zacks Equity Research
Encompass Health (EHC) and BJC HealthCare's new rehabilitation hospital is expected to come online in 2024.
Progyny (PGNY) Upgraded to Buy: Here's Why
by Zacks Equity Research
Progyny (PGNY) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
CoDiagnostics, Inc. (CODX) Surges 5.6%: Is This an Indication of Further Gains?
by Zacks Equity Research
CoDiagnostics, Inc. (CODX) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
Will Mednax's (MD) New Name Pediatrix Medical be Beneficial?
by Zacks Equity Research
Mednax's (MD) name change is expected to take effect following the closing bell on Jul 1, 2022.
UnitedHealth (UNH) Unit Eyes $1.5B EMIS Acquisition in UK
by Zacks Equity Research
UnitedHealth's (UNH) Optum business operates in the United Kingdom for two decades and the acquisition is expected to boost its footprint in the country.
HCA Healthcare (HCA) Scraps Utah Buyout Post FTC's Roadblock
by Zacks Equity Research
HCA Healthcare's (HCA) aborted acquisition follows another abandoned buyout plan involving RWJBarnabas Health and Saint Peter's Healthcare System.
Centene (CNC) Raises 2022 Guidance, Ups Share Buyback Fund
by Zacks Equity Research
Currently, Centene (CNC) has $3.6 billion remaining under its share buyback program.
Cigna (CI) Signs $3.5B Accelerated Share Buyback Agreements
by Zacks Equity Research
Cigna (CI) intends to buy back at least $7 billion worth of its stocks this year alone.
Encompass Health (EHC) Forms JV With NCH Healthcare in Naples
by Zacks Equity Research
The NCH Healthcare System's board grants approval to invest in the joint venture with Encompass Health (EHC).
Encompass Health (EHC) Plans to Distribute Enhabit Shares
by Zacks Equity Research
Every Encompass Health (EHC) shareholder will receive one Enhabit common share for every two EHC common shares held.
Should You Hold On to Teladoc Health (TDOC) Stock for Now?
by Zacks Equity Research
Teladoc Health's (TDOC) cash flows will likely gain from the growing number of visits and memberships.
HCA Healthcare's (HCA) Galen College Adds 8th New Facility
by Zacks Equity Research
HCA Healthcare's (HCA) Galen College nursing campus addition comes when the country is suffering from a nursing shortage.